Is Thermo Fisher Scientific, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Thermo Fisher Scientific, Inc. moved from expensive to fair. Based on the current metrics, the company appears fairly valued. Key ratios include a P/E ratio of 26, an EV to EBITDA of 18.39, and a Price to Book Value of 3.44. In comparison to peers, Abbott Laboratories has a P/E of 18.36 and Medtronic Plc has an EV to EBITDA of 15.08, indicating that Thermo Fisher is positioned competitively within its industry.
In terms of recent performance, Thermo Fisher's stock returned 2.69% over the past week, outperforming the S&P 500's return of 1.70%. However, its one-year return of -10.07% lags behind the S&P 500's 14.08%, suggesting that while the stock is currently fairly valued, it has struggled to keep pace with broader market trends.